血清铁蛋白联合前列腺特异性抗原检测对前列腺癌的诊断价值

目的探讨血清铁蛋白(Ferr)、总前列腺特异性抗原(tPSA)、游离前列腺特异性抗原(f PSA)、fPSA/tPSA联合检测对前列腺癌(PCa)的诊断价值。方法选择90例PCa患者、84例前列腺良性病变患者和50例健康男性体检者分别作为PCa组、良性组和对照组,检测3组研究对象的血清Ferr、tPSA、fPSA水平并计算fPSA/tPSA,分析Ferr、tPSA、fPSA、fPSA/tPSA联合检测对PCa的诊断价值。结果PCa组患者的血清Ferr、tPSA、fPSA水平均高于良性组和对照组,fPSA/tPSA低于良性组和对照组,差异均有统计学意义(P﹤0.05)。良性组患者的血清Ferr、tPSA、fPSA水平均高于对照组,fPSA/tPSA低于对照组,差异均有统计学意义(P﹤0.05)。PCa患者的血清Ferr与tPSA、fPSA均呈正相关,tPSA与f PSA呈正相关,tPSA与fPSA/tPSA呈负相关(P﹤0.05)。血清Ferr、tPSA、fPSA、fPSA/tPSA联合检测诊断PCa的灵敏度、特异度、曲线下面积均高于四个指标的三联、两联、单独检测。结论PCa患者的血清Ferr、t PSA、fPSA水平均高于前列腺良性病变患者,fPSA/tPSA低于前列腺良性病变患者。血清Ferr、tPSA、f PSA、f PSA/tPSA联合检测对PCa具有较高的诊断价值,值得在临床中推广应用。     

前列腺特异性抗原的检测对前列腺癌及前列腺增生的诊断意义

目的　探讨血清总前列腺特异性抗原 (t PSA)、游离PSA (f PSA)、PSA密度 (PSAD )及其f PSA/t PSA比值对前列腺癌 (PCa)及前列腺增生 (BPH )的诊断价值。方法　采用酶联免疫分析方法 (ELISA )检测未经治疗的 62例BPH患者和 2 4例PCa患者血清f PSA、t PSA水平 ,并计算f PSA/t PSA值和PSAD ,对检测结果进行统计学处理。结果　BPH组与PCa组的f PSA、t PSA水平均明显高于对照组 (P <0 .0 1) ;前列腺癌组的f PSA /t PSA值明显小于对照组及前列腺癌增生组 (P <0 .0 1) ;PCa组PSAD明显大于对照组和BPH组 (P <0 .0 1)。结论　检测f PSA/t PSA和PSAD比单一检测f PSA、t PSA可显著提高对PCa诊断的特异性及符合率 ,对前列腺体积较大的BPH和PCa患者 ,检测PSAD更有意义     

前列腺癌实验室诊断指标的ROC曲线分析

目的应用ROC曲线分析血清游离前列腺特异性抗原（fPSA）,总前列腺特异性抗原（tPSA）及其比值（fP-SA/tPSA）在前列腺癌中的诊断价值。方法应用受试者工作特征曲线（ROC）对健康男性组,前列腺增生组及前列腺癌组血清tPSA,fPSA及fPSA/tPSA结果进行分析。结果前列腺癌组血清的tPSA、fPSA及f/t与其余两组比较均有差异。经ROC曲线分析,tPSA、fPSA及f/t的阈值分别为7.14μg/L、1.31μg/L及0.235。三者分别及联合检测的ROC曲线下面积分别为0.905、0.770、0.352与0.968。结论 tPSA、fPSA及f/t三者联合检测可以提高对前列腺癌的诊断。     

游离和总前列腺特异性抗原比值、外周血中性粒细胞和淋巴细胞比值、白细胞介素6、前列腺健康指数密度检测在前列腺癌早期诊断中的应用

目的探讨游离和总前列腺特异性抗原比值(f/tPSA)、外周血中性粒细胞和淋巴细胞比值(NLR)、白细胞介素6(IL-6)、前列腺健康指数密度(PHID)检测在前列腺癌早期诊断中的临床应用。方法回顾性分析2020年1月至2022年1月徐州医科大学第二附属医院收治住院的160例前列腺特异性抗原(PSA)异常患者临床资料, 根据前列腺穿刺活组织检查或电切手术病理结果分为前列腺癌组68例、良性前列腺增生组92例;选取同期徐州医科大学第二附属医院男性健康体检者50名为健康对照组。3组均检测总前列腺特异性抗原(tPSA)、游离前列腺特异性抗原(fPSA)、前列腺特异性抗原同源异构体2(p2PSA)、IL-6等指标, 计算f/tPSA、前列腺健康指数(PHI)、PHID和NLR等。绘制受试者工作特征曲线(ROC), 比较各指标诊断和鉴别诊断前列腺癌、良性前列腺增生的效能。结果前列腺癌组患者血清tPSA、fPSA、p2PSA、PHI、PHID水平均高于良性前列腺增生组和健康对照组(均P<0.05);血清f/tPSA水平均低于良性前列腺增生组和健康对照组(均P<0.05)。PHID诊断早期前...     

血清cPSA对前列腺癌诊断价值的研究

 目的　探讨血清中结合前列腺特异性抗原 (c PSA)在前列腺癌 (PCa)诊断中的临床价值。方法　用磁微粒子免疫化学发光法测定 72例良性前列腺增生 (BPH)患者和 38例PCa患者c PSA、t PSA ,并计算c PSA/t PSA比值。结果　c PSA及c PSA/t PSA比值可有效地区分BPH和PCa(P <0 .0 0 5 ) ,尤其是在诊断灰值区 (t PSA为 4～ 1 0ng/ml)时效果更显著。在以t PSA≤1 0 .0ng/ml和c PSA/t PSA≥0 .72为筛选界值联合对PCa进行筛选时 ,临床概率敏感度为 93.8%。结论　c PSA的引入及c PSA/t PSA比值的应用 ,对PCa的诊断具有重要临床意义 ,尤其是在前列腺特异性抗原的诊断灰值区。     

血清PSA及fPSA/tPSA比值在前列腺癌骨转移诊断中的价值

目的:通过分析前列腺癌患者血清中前列腺癌特异性抗原（PSA）浓度和游离前列腺特异性抗原（fPSA）/总前列腺特异性抗原（tPSA）与骨转移的关系,探讨血清PSA和fPSA/tPSA在诊断前列腺癌骨转移中的价值。方法:采用电化学发光法检测74例前列腺癌患者血清中的fPSA、tPSA浓度并计算fPSA/tPSA,并对所有前列腺癌患者进行全身骨扫描显像。结果:74例前列腺癌患者当中无骨转移的29例,有骨转移的45例,分别占前列腺癌患者的39.2％和60.8％。在发生骨转移的前列腺癌患者当中单一病灶的有5例,占11.1%,其中3例转移灶在骨盆,2例在椎体;转移灶为两处的有3例,占6.7%;三处或三处以上转移的有37例,占82.2%。从骨转移发生的部位来看,椎体转移的最多,有35例;其次为骨盆转移,有31例;发生肋骨转移的有28例;四肢骨转移的有9例;其它部位转移的有2例。前列腺癌骨转移组和无骨转移组的PSA和fPSA/tPSA分别为（57.68±38.67） ng/ml、0.14±0.08和（21.61±17.87） ng/ml、0.25±0.09,差异均有统计学意义（P<0.05）。结论:前列腺癌骨转移以多发病灶为主,且病灶主要发生在脊柱和骨盆。前列腺癌患者随血清PSA浓度的升高,fPSA/tPSA比值降低,发生骨转移的比例增高,当PSA>20.00 ng/ml或fPSA/tPSA≤0.15时,诊断前列腺癌骨转移的灵敏度和特异度较高。     

前列腺癌与前列腺增生患者血清游离PSA和总PSA的改变

背景与目的:血清总前列腺特异性抗原(totalprostate-specificantigen,TPSA)被认为是目前诊断前列腺癌(carcinomaofprostate,PCa)的最佳肿瘤标记物,游离前列腺特异性抗原(freeprostatespecificantigen,FPSA)与TPSA的比值(FPSA/TPSA)可以提高其诊断PCa的特异性。本研究比较PCa与前列腺增生(benignprostatehyperplasia,BPH)患者血清TPSA及FPSA/TPSA比值水平,为临床诊断PCa提供参考。方法:用酶联免疫法检测66例BPH患者、29例BPH合并急性尿潴留(acuteurinaryretention,AUR)患者及22例PCa患者的血清TPSA、FPSA值,并对三组患者的血清TPSA及FPSA/TPSA的差异进行比较分析。结果:BPH患者血清TPSA(4.10±1.39)μg/L、BPH合并AUR患者血清TPSA(15.50±3.34)μg/L与PCa患者血清TPSA(55.00±13.50)μg/L之间均有显著性差异(P<0.05)。但三组患者血清TPSA在<4.0μg/L、4.0～10.0μg/L、>10.0μg/L区间存在重叠,BPH合并AUR患者与PCa患者重叠更为明显;BPH患者和BPH合并AUR者的FPSA/TPSA值无显著性差别(P>0.05),但与PCa患者比较均有显著性差异(P<0.05);三组患者FPSA/TPSA水平在<0.15、0.15～0.25、>0.25区间均存在重叠。结论:TPSA、FPSA/TPSA在BPH患者、BPH合并AUR患者和PCa患者中均存在重叠。血清TPSA、FPSA/TPSA水平临床上     

不同年龄组男性总前列腺特异性抗原水平的检测及其临床意义

目的探讨不同年龄组男性总有列腺特异性抗原（tPSA）水平检测及其临床意义。方法将588名男性体检者根据年龄分为4组：青年组（〈45岁）125例，中年组（45-60岁）142例，普通老年组（60-75岁）169例和高龄老年组（≥75岁）152例；分析各年龄组的前列腺疾病情况和tPSA水平；各年龄组不同前列疾病情况的tPSA总水平及在不同水平（≤4ng／ml、4-10ng／ml和〉10ng／m1）的分布情况。结果①青年组和中年组的水平高于老年组，前列腺疾病的发生率和tPSA水平均低于老年组（P〈0．01）；高龄老年组的水平低于普通老年组（P〈0．01），前列腺癌发生率（P〈0．05）和tPSA（P〈0．01）高于普通老年组；②各年龄组及总体依据前列腺疾病严重情况tPSA水平均上升，且两两之间差异有统计学意义；青年和中年两组的正常者和前列腺炎的tPSA水平均低于老年组，高龄老年组良性前列腺增生的tPSA水平高于中年组和普通老年组；③随着前列腺疾病严重程度的增加，各组tPSA水平≤4ng／ml的分布降低；tPSA水平≥10ng／ml的分布增多；随年龄增大，各组对应正常和疾病情况的tPSA水平≤4．g／ml的分布降低，tPSA水平≥10ng／ml的分布增多。结论tPSA水平在不同年龄组同一类型前列腺疾病和同年龄段不同前列腺疾病的水平不同，提示tPSA水平受年龄因素的影响，tPSA水平的检查可用于前列腺疾病的初期诊断。     

前列腺特异性抗原的初步应用

为了探讨前列腺特异性抗原（ＰＳＡ）在临床中的作用，本文用夹心ＥＬＩＳＡ法检测了７７人份血清ＰＳＡ浓度。结果显示，前列腺癌组病人血清ＰＳＡ为３７．５５±２５．９５（ｘ±ｓ，μｇ／Ｌ，下同）；良性前列腺增生组为６．７８±５．６７；健康对照组为２．８０±０．５２，三者之间均有显著性差异（Ｐ＜０．０１）。将ＰＳＡ值与年龄作相关分析，得ｒ＝０．５２，Ｐ＜０．００４。结果表明，血清ＰＳＡ是诊断前列腺癌的一个很有用的指标，正常男性以ＰＳＡ≤４μｇ／Ｌ为正常值是恰当的，但在分析６０岁以上的病例时，其正常值可适当上调     

前列腺特异性膜抗原在前列腺癌患者外周血和组织中的表达及意义

目的探讨前列腺特异性膜抗原（PSMA）在前列腺癌患者（PCa）外周血和组织中的表达及其与肿瘤病理分级和临床分期之间的关系。方法采用RT-PCR方法检测前列腺特异性膜抗原（PSMA）在前列腺癌和良性增生患者外周血清中的表达;采用免疫组化法观察PSMA在前列腺不同病变组织中的表达。前列腺癌28例,前列腺上皮内瘤（PIN）7例,良性前列腺增生（BPH）30例。结果血清学检测显示PSMA mRNA在前列腺癌和良性病变组（包括PIN和BPH）患者外周血中阳性率分别为67.9%和8.1%,两者差异具有显著性（P〈0.01）。在局限性癌、局部进展性癌和远处转移癌患者外周血肿瘤细胞中,PSMA mRNA的阳性率分别为58.3%、66.7%和85.7%,随前列腺癌临床分期的进展而逐渐递增（P〈0.05）。在高分化、中分化和低分化前列腺癌中,PSMA mRNA的阳性率分别为87.5%、62.5%和50%,肿瘤分化越差,其阳性率越低（P〈0.05）。组织学检测显示PSMA在PCa、PIN、BPH三种不同前列腺病变组织中的阳性率分别为60.7%、28.6%和20.0%（P〈0.05）,在高、中、低分化前列腺癌组织中PSMA的阳性率分别为100.0%、50.0%和25.0%,与肿瘤Gleason评分之间呈负相关（P〈0.05）。在局限性癌、局部进展性癌和远处转移癌患者肿瘤组织中,PSMA的阳性率分别为58.3%（7/12）、77.8%（7/9）和42.9%（3/7）（P〉0.05）。结论PSMA在前列腺癌组织中明显高表达,并且表达量与前列腺癌临床分期和分化程度（组织学分级）密切相关;检测PSMA可能对前列腺癌诊断、治疗方案的选择及预后评估具有重要价值。     

Molecular forms of prostate‐specific antigen in serum with concentrations of total prostate‐specific antigen <4 μg/L: Are they useful tools for early detection and screening of prostate cancer?

Molecular forms of prostate-specific antigen (PSA) improve the differentiation between benign prostatic hyperplasia (BPH) and prostate cancer (PCa) in men with total PSA concentrations between 4 and 10 microg/l. To evaluate the diagnostic utility of free PSA (fPSA) and complexed PSA forms for identification of men with PCa in the low PSA range of <4 microg/l, total PSA (tPSA), alpha(1)-antichymotrypsin complexed PSA (PSA-ACT) and fPSA (Roche Elecsys [ES] system) as well as tPSA and complexed PSA (cPSA) (Bayer Immuno 1 system) were measured in archival serum samples from 31 untreated patients with PCa, 66 patients with BPH, and 90 men without prostatic disease. The median ratios of fPSA/tPSA, PSA-ACT/tPSA and cPSA/tPSA were significantly different between patients with BPH and PCa (27.2 vs. 19.4%, 64 vs. 88%, 77.2 vs. 88.2%, p < 0.05). No associations between PSA forms and tumor stage and grade were found. Analysis of the receiver operating characteristic curves showed that these ratios could discriminate better between BPH and PCa patients than determination of the analytes tPSA, fPSA, cPSA and PSA-ACT alone. The use of one of the ratios would have eliminated roughly half of the unnecessary biopsies in this study. The ratios should be considered as potential tools to increase the selectivity of PCa detection at low PSA concentration. The ratios fPSA/tPSA and cPSA/tPSA can be determined using commercially available assays so that one of these ratios could be preferred instead of PSA-ACT determination. The ratios could be useful in assessing the risk of PCa in the individual and therefore in deciding on prostate biopsy for final diagnosis.     

PSAD和游离/总PSA比值在前列腺癌诊断中的意义

 目的　比较研究前列腺特异抗原(PSA)、PSA密度(PSAD)和游离/总PSA比值(F/TPSA)在前列腺癌诊断中的价值。方法　41例前列腺增生和22例前列腺癌患者,术前用放免法测定血清PSA和游离PSA。所有患者经直肠腔内B超测出前列腺体积,求得PSAD,用t检验比较分析。结果　前列腺癌组的PSA、PSAD均显著高于前列腺增生组(PSA：46.3±33.8μg/Lvs7.04±6.91μg/L,P=0.000021;PSAD：1.43±1.21μg。L-1。ml-1vs0.14±0.15ng。ml-1。ml-1,P=0.000055)。两组的F/TPSA比值无显著差异(0.18±0.11vs0.22±0.18,P=0.34)。结果　PSA和PSAD是鉴别前列腺癌的良好指标,对于PSA可疑者,PSAD有助于区分前列腺癌和前列腺增生,本组游离/总PSA比值不能帮助鉴别诊断。     

Evaluation of free-to-total prostate specific antigen ratio in the diagnosis of prostate cancer

It'sreportedthatfreetototalprostatespecificantigenration(f/tPSA)canprovidemorebenefitthanthesingleuseofprostatespecificantigen(PSA)inthediagnosisofprostatecancer(PCa).WemeasuredserumPSAandfPSAlevelsin62casesofbenignprostatichyperplasia(BPH)and40casesofPCausingradioimmunoassay,withpatients'agerange59y-89y.RESULTSPSA,fPSAandf/tPSAareshowninTable1.BoththesetwogroupsshowslinearcorrelationbetweenPSAandfPSA,correlationcoefficientofBPHis0.55(P<0.01),ofPCais0.44(P<0.01).Twoslopesha…     

Limited usefulness of the free-to-total prostate-specific antigen ratio for the diagnosis and staging of prostate cancer in Japanese men

Background The objective of this study was to evaluate the clinical significance of measuring the free-to-total (f/t) prostate-specific antigen (PSA) ratio for the differentiation of prostate cancer from benign prostatic hypertrophy (BPH) and for the staging of prostate cancer in Japanese men.Methods Before treatment, tPSA and fPSA were measured in 147 patients with prostate cancer and in 253 with BPH, using immunofluorometric techniques. Furthermore, the f/t PSA ratio and the tPSA density of the whole prostate (PSAD) were calculated.Results The tPSA and PSAD levels in patients with prostate cancer paralleled the clinical stage, and were significantly higher than the levels in patients with BPH, while the f/t PSA ratio was not associated with clinical stage, despite the significantly lower values in prostate cancer patients than in BPH patients. Furthermore, the tPSA and PSAD values, but not the f/t PSA ratio, were significantly different between patients with pathologically extraprostatic disease and those with organ-confined disease. Calculation of the specificity of each assay within the range of 80%–95% sensitivity showed that tPSA and PSAD provided better specificities than the f/t PSA ratio. However, there was no significant difference in specificities among these three assays. In prostate cancer and BPH patients with PSA values of 4.1–10ng/ml, the specificities of tPSA and PSAD were also superior to that of the f/t PSA ratio.Conclusion These findings suggest that measurement of the f/t PSA ratio does not provide any significant additional information for the diagnosis and staging of prostate cancer in Japanese men when tPSA and PSAD values are available.     

A new Model Consists of Intravesical Prostatic Protrusion,Prostate Volume and Serum Prostatic-Specific Antigen in the Evaluation of Prostate Cancer

The Prostate-specific antigen (PSA) level is largely used to diagnose prostate cancer (PCa) in last decades. However, its specificity is low in patients with a PSA level ranging from 4.0 to 10.0 ng/ml. This study aims to define the correlation between intravesical prostatic protrusion (IPP) and PSA and to establish a new model to predict PCa. A total of 339 patients order than 45 years examined between October 2010 and June 2012 were enrolled. Eligible patients were recommended for transrectal ultrasonography (TRUS)-guided prostate biopsies after measuring total prostate volume (TPV), tranzisional zone volume (TZV) and IPP. The levels of total PSA (tPSA), free PSA (fPSA) were analyzed by using Hybritech calibrated Access tPSA and fPSA assays. A new mathematical model, named IPP removed PCa predicting score (IRPPS), consists of tPSA, TZV and IPP was established. The predictive accuracy of IRPPS, PSA density (PSAD), %PSA and tPSA were compared using receiver-operator characteristic (ROC) analysis. Eighty-six patients had PSA levels of 4.0–10.0 ng/ml. Twenty of them were diagnosed as PCa. Using ROC curves, the areas under the curve for IRPPS, PSAD and %PSA and tPSA were 0.786, 0.768 and 0.664 and 0.585, respectively. We suggested IPP grade had a significant relationship with serum tPSA levels. The predictive accuracy of IRPPS was higher than the other 3 indictors.     

ROC曲线分析波谱定量分析在前列腺癌中的诊断价值

目的：探讨MR波谱（magnetic resonance spectroscopy,MRS）定量分析方法在前列腺癌（prostatic carci-noma,PCa）诊断中的意义。方法：对所有疑诊PCa患者行前列腺磁共振波谱分析,酶联免疫法测定血清前列腺特异抗原（PSA）,经直肠超声测定前列腺体积,计算前列腺特异抗原密度（PSAD）,经超声引导下系统穿刺活检证实的71例良性前列腺增生患者和31例PCa患者,分别测量各个位置（胆碱＋肌酸）/枸橼酸盐[（Cho＋Cre）/Cit]的比值,并取均值。结果：前列腺穿刺阳性组的PSA、PSAD及（Cho＋Cre）/Cit的比值分别为23.73±19.06、0.62±0.42、2.33±0.66;前列腺穿刺阴性组的PSA、PSAD及（Cho＋Cre）/Cit的比值分别为8.61±4.47、0.15±0.13、0.73±0.39。阳性组的检测值均较阴性组高（P〈0.05）。PSA、PSAD及（Cho＋Cre）/Cit在ROC曲线下的面积分别为0.71、0.76、0.84。在保持93.5%的敏感性以上时,PSA、PSAD及（Cho＋Cre）/Cit的特异性是43.7%、63.4%和83.1%,（Cho＋Cre）/Cit较PSA、PSAD能更好地检出PCa。结论：MRS分析方法定量评价PCa的代谢改变,有助于PCa的早期诊断,同时结合PSA、PSAD更有助于前列腺癌诊断的特异性。     

Significance of prostate-specific antigen--alpha(1)-antichymotrypsin complex for diagnosis and staging of prostate cancer.

OBJECTIVE: To evaluate the clinical significance of measuring the prostate-specific antigen-alpha(1)-antichymotrypsin (PSA-ACT) for differentiating prostate cancer from benign prostate hypertrophy (BPH) and for the staging of prostate cancer. METHODS: Before treatment, total PSA (tPSA) and PSA-ACT were measured in 120 patients with prostate cancer and in 150 patients with BPH using immunofluorometric techniques with different monoclonal antibodies against PSA and ACT. Furthermore, the tPSA and PSA-ACT densities of the whole prostate (PSAD and ACTD, respectively) were calculated. RESULTS: tPSA, PSAD, PSA-ACT and ACTD levels in patients with prostate cancer paralleled the clinical stage and were significantly higher than those in patients with BPH. Furthermore, these four values were significantly higher in patients with pathologically extraprostatic disease than those with organ-confined disease. Receiver operating characteristics analysis among patients with PSA values of 4.1-10 ng/ml revealed that the areas under the curve for tPSA and ACTD were similar to those for PSA-ACT and ACTD, respectively and that no significant differences in the differentiation between prostate cancer and BPH were observed among these parameters. CONCLUSIONS: Measurement of PSA-ACT provides useful information for the clinical staging of prostate cancer and differential diagnosis between prostate cancer and BPH; however, compared with tPSA, PSA-ACT may not be significantly superior in the diagnosis and staging of prostate cancer.     

Diagnostic Role of Serum Free-to-Total Prostate Specific Antigen (PSA) Ratio in Prostate Cancer with Serum Total Concentration of PSA below 4 ng/mL

Purpose: To examine the effectiveness of serum free-to-total prostate specific antigen ratio (%fPSA) forthe detection of prostate cancer (PCa) in men with different serum total PSA (tPSA) categories. Materials andMethods: From January 2010 to December 2013, a total of 225 patients with lower urinary tract symptoms(LUTS) underwent tPSA and %fPSA measurements. Histological examination with calculation of Gleasonscore and whole body bone scans were performed in identified cases of PCa. Results: PCa was diagnosed in 44(19.6%) patients and the remaining 181 patients had benign prostate disease. PCa was detected in 5 (23.8%),13 (8.7%) and 26 (47.3%) cases with tPSA level ranges ≤4 ng/ml, 4 to 10 ng/ml and >10 ng/ml, respectively. Theaverage Gleason score was 7.2±0.2. Some 6 (13.6%) out of 44 PCa patients had bone metastases. The sensitivitywas 80% and specificity was 81.3% at the cut-off %fPSA of 15% in PCa patients with a tPSA level below 4 ng/mL. A lower %fPSA was associated with PCa patients with Gleason score ≥7 than those with Gleason score≤6 (11.7±0.98 vs. 16.5±2.25%, P=0.029). No obvious relation of %fPSA to the incidence of bone metastasis wasapparent in this study. Conclusions: The clinical application of %fPSA could help to discriminate PCa frombenign prostate disease in men with a tPSA concentration below 4 ng/mL.     

Predictive Value of the Platelet-To-Lymphocyte Ratio in Diagnosis of Prostate Cancer

Purpose: To predict prostatic carcinoma using a logistic regression model on prebiopsy peripheral bloodsamples. Materials and Methods: Data of a total of 873 patients who consulted Urology Outpatient Clinics of FatihSultan Mehmet Training and Research Hospital between February 2008 and April 2014 scheduled for prostatebiopsy were screened retrospectively. PSA levels, prostate volumes, prebiopsy whole blood cell counts, neutrophiland platelet counts, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), biopsy resultsand Gleason scores in patients who had established diagnosis of prostate cancer (PCa) were evaluated. Results:This study was performed on a total of 873 cases, with an age range 48-76 years, divided into three groups asfor biopsy results. with diagnoses of benign prostatic hyperplasia (BPH) (n=304, 34.8 %), PCa (n=265, 30.4 %)and histological prostatitis (n=304; 34.8 %). Intra- and intergroup comparative evaluations were performed.White blood cell and neutrophil counts in the histological prostatitis group were significantly higher than thoseof the BPH and PCa groups (p=0.001; p=0.004; p<0.01). A statistically significant intergroup difference wasfound for PLR (p=0.041; p<0.05) but not lymphocyte count (p>0.05). According to pairwise comparisons, PLRwere significantly higher in the PCa group relative to BPH group (p=0.018, p<0.05, respectively). Though notstatistically significant, higher PLR in cases with PCa in comparison with the prostatitis group was remarkable(p=0.067, and p>0.05, respectively). Conclusions: Meta-analyses showed that in patients with PSA levels over4 ng/ml, positive predictive value of PSA is only 25 percent. Therefore, novel markers which can both detectclinically significant prostate cancer, and also prevent unnecessary biopsies are needed. Relevant to this issuein addition to PSA density, velocity, and PCA3, various markers have been analyzed. In the present study, PLRw ere found to be the additional predictor of prostatic carcinoma.